Bemdaneprocel, a novel stem cell-derived therapy being developed by Bluerock Therapeutics, maintained a favorable safety profile and good tolerability in people with Parkinson’s disease over three years in a Phase 1 trial, new data show. Importantly, the long-term findings from the completed exPDite study (NCT04802733) also show…
Neurosurgeons temporarily implanted a tiny device into the brains of three people with Parkinson’s disease to collect data on a poorly known brain region, with the goal of understanding how Parkinson’s affects executive function. Doctors at the University of Colorado Anschutz — the first site authorized by the U.S.
The Michael J. Fox Foundation (MJFF) has awarded a grant to Valo Health to support the development of new treatments targeting the underlying causes of Parkinson’s disease. The funding will allow researchers to use artificial intelligence to uncover the root causes of the disease and identify new…
Boosting levels of a protein called TFE3 helped reduce nerve cell degeneration and improve motor function in a mouse model of Parkinson’s disease, a study found. Increased levels of this protein helped clear toxic alpha-synuclein clumps, a hallmark of Parkinson’s, as well as restore the function of mitochondria, the…
Two imaging markers can help pinpoint sites of brain inflammation in people with Parkinson’s disease, according to a study. The findings shed light on the role of brain inflammation in disease progression and can help pave the way for more precise diagnostics and targeted therapies. “We are excited about…
Wearable sensors that monitor motor symptoms like tremor can accurately assess eligibility of Parkinson’s disease patients for apomorphine pump therapy, aligning closely with traditional clinical evaluations, according to a study. The findings suggest that wearable sensors have “the potential to revolutionize the way patients are assessed and treated, ultimately…
Cyrano Therapeutics is supporting an investigator-initiated clinical study that will evaluate CYR-064, its leading nasal candidate therapy, to restore smell loss in Parkinson’s disease. The study, led by neurologist David Silvers, MD, in Palm Beach Gardens in Florida, seeks to enroll 15 to 20 adults, ages 18-80, with…
Creative arts therapy, or an expressive therapeutic approach that engages people in various creative activities, can reduce anxiety in individuals with Parkinson’s disease and improve their well-being — while potentially lessening their need for healthcare services — according to the results of a small pilot study conducted in Europe.
Gain Therapeutics has set up a clinical advisory board made up of leading Parkinson’s experts in genetics, biomarkers, and trial design to guide the advancement of GT-02287, its investigational therapy for Parkinson’s disease. The advisory board will collaborate with Gain’s leadership to guide GT-02287 through its potential Phase…
A new screening method may shed light on the interactions between genetic variants that increase the risk of Parkinson’s disease, providing potential avenues for improving risk prediction and personalized care, a study found. The tool, Variant-variant Interaction through Variable Thresholds (VARI3), is designed to detect and interpret how genetic…
Get regular updates to your inbox.
